Market Place
Sourcing Support
FDA Confirms Para IV Patent for Capmatinib (Tabrecta) Tablets
11 Jul 2024 //
FDA
Chugai obtains Japanese approval for FoundationOne Liquid CDx Genomic Profile
27 May 2023 //
PHARMABIZ
FDA approves capmatinib for metastatic non-small cell lung cancer
10 Aug 2022 //
US FPOOD & DRUG
Novartis lung cancer drug Tabrecta gets approval
22 Jun 2022 //
PHARMATIMES
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®)
22 Apr 2022 //
BUSINESSWIRE
Novartis` Tabrecta gets EMA panel backing to treat lung cancer subtype in EU
22 Apr 2022 //
SEEKINGALPHA
Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta)
02 Sep 2020 //
BUSINESSWIRE
Novartis announces NEJM publication of pivotal study of Tabrectaâ„¢
02 Sep 2020 //
PRESS RELEASE
FDA starts quick review of Merck’s MET-targeting lung cancer drug
28 Aug 2020 //
PHARMAPHORUM
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.